

Sun, Glenmark nervous system drug gets FDA nod

25 June 2013 | News | By BioSpectrum Bureau



New Delhi: The nervous system drug, Riluzole, by Indian drug majors Sun Pharma and Glenmark received the much awaited US FDA nod.

The US regulator has given its approval to these companies to sell generic versions of nervous system disorder treatment drug Riluzole.

The US FDA said on their website that approvals have been issued for generic Riluzole oral tablets in the strength of 50 mg. The tablets that are indicated for treatment of amyotrophic lateral sclerosis has garnered sales of \$64 million in the US market, as per IMS Health Sales data for 12 months, till March 2013.